Anebulo Pharmaceuticals Reports Q4 Loss of $2.14mln, Down from $1.35mln YoY

Anebulo Pharmaceuticals reported a Q4 loss of -$2.14 million, compared to a loss of -$1.35 million last year. Earnings per share remained the same at -$0.05. The company's earnings are based on GAAP.

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB) has released its financial results for the fourth quarter and fiscal year ending June 30, 2025. The company reported a net loss of $2.14 million for the quarter, an increase from the $1.35 million loss in the same period last year. The earnings per share (EPS) remained unchanged at -$0.05 Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Recent Updates^[1].

Operating expenses for the fourth quarter of fiscal 2025 were $2.3 million, up from $1.3 million in the same period last year. The company's cash and cash equivalents totaled $11.6 million as of June 30, 2025, with an additional $3 million available through a loan agreement Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Recent Updates^[1].

For the full fiscal year 2025, operating expenses were $9.2 million, up from $8.3 million in the prior year. The net loss for the year was $8.5 million, an increase from the $8.2 million loss in fiscal 2024. The increase in net loss was primarily due to higher research and development expenses related to pre-clinical and clinical studies of selonabant, the company's lead drug candidate Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Recent Updates^[1].

Anebulo Pharmaceuticals initiated a Phase 1 single ascending dose (SAD) study of an intravenous (IV) formulation of selonabant during the fourth quarter. The study, conducted in Austin, Texas, aims to assess the safety, tolerability, and pharmacokinetics of IV-administered selonabant in healthy adult subjects aged 18 to 25 years Anebulo Pharmaceuticals Reports Fourth Quarter and ...^[2]. The company also received the second-year tranche of $994,300 from an ongoing collaborative grant from the National Institute on Drug Abuse (NIDA) of the National Institutes of Health (NIH) to support this study Anebulo Pharmaceuticals Reports Fourth Quarter and ...^[2].

The company's Board of Directors has approved a proposed going private transaction, which includes a reverse stock split of the company's common stock. The primary goal of this reverse stock split is to maintain the number of record holders of common stock below 300, thereby reducing the company's obligation to file public reports with the SEC. The company plans to hold a special meeting of stockholders to approve the reverse stock split, although there is no definitive timetable for the completion of this process Anebulo Pharmaceuticals Reports Fourth Quarter and ...^[2].

Anebulo Pharmaceuticals' Chief Executive Officer, Richie Cunningham, commented on the company's progress, emphasizing the potential of selonabant as the first emergency antidote for acute cannabis-induced toxicity in children. Cunningham highlighted the serious and potentially life-threatening consequences of acute cannabis exposure in children and the company's focus on developing an IV formulation of selonabant for faster approval relative to the adult oral product Anebulo Pharmaceuticals Reports Fourth Quarter and ...^[2].